CervoMed Drug Cut Dementia Progression Risk By 75% In Trial CervoMed's Phase 2b trial shows neflamapimod reduces dementia progression and plasma GFAP, with significant cognitive improvements in Lewy body dementia patients.
CervoMed's Dementia Data Show Slowed Disease Progression CervoMed reports 32-week data showing neflamapimod slowed DLB progression and reduced neurodegeneration biomarkers with good tolerability.
Traders are paying attention to the gapping stocks in Monday's session. Traders are paying attention to the gapping stocks in Monday's session. Let's dive into which stocks are experiencing notable gaps.
What's going on in today's pre-market session Discover the top movers in Monday's pre-market session and stay informed about market dynamics.
EXCLUSIVE: March's 20 Most-Searched Tickers On Benzinga Pro — Where Do Tesla, Nvidia, Apple, Applovin Stock Rank? A look at the top 20 most-searched stocks on Benzinga Pro in March. While many had news in the month that could affect rankings, the trends could be a sign of what's to come.
